- Home
- BLRX vs UCL Comparison
BLRX vs UCL Comparison
Compare BLRX & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- UCL
- Stock Information
- Founded
- BLRX 2003
- UCL 2014
- Country
- BLRX Israel
- UCL Hong Kong
- Employees
- BLRX N/A
- UCL N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- UCL Telecommunications Equipment
- Sector
- BLRX Health Care
- UCL Consumer Discretionary
- Exchange
- BLRX Nasdaq
- UCL Nasdaq
- Market Cap
- BLRX 15.3M
- UCL 70.6M
- IPO Year
- BLRX 2011
- UCL 2020
- Fundamental
- Price
- BLRX $4.52
- UCL $2.22
- Analyst Decision
- BLRX Strong Buy
- UCL
- Analyst Count
- BLRX 2
- UCL 0
- Target Price
- BLRX $19.00
- UCL N/A
- AVG Volume (30 Days)
- BLRX 64.3K
- UCL 51.2K
- Earning Date
- BLRX 08-14-2025
- UCL 08-13-2025
- Dividend Yield
- BLRX N/A
- UCL N/A
- EPS Growth
- BLRX N/A
- UCL N/A
- EPS
- BLRX N/A
- UCL 0.09
- Revenue
- BLRX $22,340,000.00
- UCL $92,256,000.00
- Revenue This Year
- BLRX N/A
- UCL $6.09
- Revenue Next Year
- BLRX N/A
- UCL $7.01
- P/E Ratio
- BLRX N/A
- UCL $20.90
- Revenue Growth
- BLRX 91.68
- UCL 7.65
- 52 Week Low
- BLRX $2.30
- UCL $0.80
- 52 Week High
- BLRX $35.60
- UCL $3.30
- Technical
- Relative Strength Index (RSI)
- BLRX 50.14
- UCL 60.04
- Support Level
- BLRX $4.40
- UCL $1.82
- Resistance Level
- BLRX $5.06
- UCL $1.96
- Average True Range (ATR)
- BLRX 0.34
- UCL 0.11
- MACD
- BLRX -0.02
- UCL -0.01
- Stochastic Oscillator
- BLRX 46.53
- UCL 44.12
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.